(888) 645-1617

News

Sort By

Bayer, J&J Win 2nd Xarelto Trial

upset lawyer sitting on courthouse steps

The second bellwether trial over the safety of the blood thinner Xarelto has ended with a second verdict in favor of drug makers Bayer and Johnson & Johnson.

The trial in federal court in New Orleans involved the family of Sharyn Orr, who died in May 2015 at the age of 67 following a hemorrhagic stroke about a year after she started taking Xarelto for atrial fibrillation. Before she died, Orr was in a coma for 10 days. Her family’s lawyer contended her death was “completely avoidable.”

The drug companies argued that Orr had several underlying conditions that contributed to her death, and that Xarelto was not to blame.

Jurors deliberated three hours before ruling in favor of the drug companies.

This was the second trial in which jurors sided with the pharmaceutical giants. The other case ended in early May in the case of Joseph Boudreaux, 75, who was hospitalized in intensive care with gastrointestinal bleeding that began less than a month after he was prescribed Xarelto for atrial fibrillation, an irregular heartbeat that causes poor blood flow.

On Monday, June 12, the same day as the Orr verdict was handed up, lawyers for Boudreaux, filed a motion for a new trial, arguing that the judge improperly prevented them from presenting evidence that would have helped jurors understand their case.

In a statement to Reuters after the Orr case ended, Bayer said the two verdicts “affirm both the safety and efficacy of Xarelto, and that its FDA-approved label contains accurate, science-based information on the benefits and risks of this life-saving medicine.”

Plaintiffs Vow to Continue Fight

Andy Birchfield and Brian Barr, co-lead counsel for the plaintiffs, told the news agency they “will continue to press forward with the legal claims of the thousands of innocent victims of this drug.”

“All medications have risks and benefits, and this one has a huge benefit and it has risks,’’ Beth Wilkinson, the companies’ lawyer, told jurors Monday, according to Bloomberg. “When put in context of all patients who have to take it, the risks are still small.’’

Xarelto was the biggest revenue generator for Bayer, bringing in $3.2 billion in sales in 2016. The drug was the third-highest revenue generator for Johnson & Johnson, where it brought in $2.5 billion in 2016.

The drug is advertised as a safer alternative to warfarin. But when patients experience the side effect of bleeding, there is no antidote, and bleeding can be fatal. When that side effect occurs with warfarin, doctors can administer a vitamin K antidote, or another option, to stop it.

According to the U.S. Food and Drug Administration, nearly 400 deaths have been associated with use of Xarelto.

Drug Makers Face 18K Lawsuits

Bayer and Johnson & Johnson are facing more than 18,000 lawsuits involving patients who claim they were injured from taking Xarelto (rivaroxaban). The lawsuits say the drug makers downplayed the risks of taking Xarelto. The next case is scheduled to go to trial in August in Mississippi.

These cases have been designated as bellwethers, or test cases, which are intended to help determine the direction of the huge number of cases that have been filed. Legal rulings and verdicts in bellwether cases have ramifications far beyond the specific lawsuits involved, and are intended to influence how and whether the remaining cases settle.

The FDA approved Xarelto in 2011. It’s part of a new class of anticoagulants, or blood-thinner drugs, which also includes Pradaxa and Eliquis, used to reduce the risk of blood clots and protect against strokes. The class of drugs is known as Factor Xa inhibitors.

Blood clots can be life threatening in patients with conditions such as pulmonary embolism and deep vein thrombosis, as well as atrial fibrillation. Unlike older blood thinners like as warfarin, the new class of drugs doesn’t require doses specific to individuals. Rather, the newer drugs are given to all patients in the same amounts, conveniently, once a day.

Initially, the drug was approved for patients with knee and hip replacement surgery, as well as atrial fibrillation. The FDA later also approved it for use in patients with deep vein thrombosis and pulmonary embolism.

Last modified: June 14, 2017


Elaine Silvestrini is a career journalist with a strong desire to learn, explain, and help people. While working at Drugwatch, Elaine has reported on breaking news involving prescription drugs and medical devices and has written pieces on several large pharmaceutical companies and other topics. She is dedicated to telling people what they need to know about developments in the news, and helping consumers understand what they can do when something goes wrong with their drugs and medical devices.

Hide Sources

  1. In Re: Xarelto Products Liability Litigation. (2017, June 12). Case 2:14md02592. U.S. District Court Eastern District of Louisiana. Minute entry.
  2. Raymond, N. (2017, June 12). Bayer, J&J win second U.S. trial over Xarelto bleeding risks. Retrieved https://www.reuters.com/article/us-bayer-xarelto-idUSKBN1932HO
  3. Fisk, M.C. and Hasselle, D. (2017, June 12). J&J, Bayer Win Second Trial Over Blood-Thinning Drug Risks. Retrieved https://www.bloomberg.com/news/articles/2017-06-12/j-j-bayer-win-second-trial-over-blood-thinning-drug-risks
  4. Raymond, N. (2017, May 3). Bayer, J&J win first trial over Xarelto bleeding risks. Retrieved http://www.reuters.com/article/us-bayer-xarelto-idUSKBN17Z2HW
Free Xarelto Case Review

Did you experience uncontrolled bleeding after taking Xarelto?
Free Case Review